{"id":"naftidrofuryl","rwe":[{"pmid":"41224747","year":"2025","title":"Naftidrofuryl mitigates LPS-induced pulmonary injury through macrophage polarization and NLRP3/TLR4 regulation, an in vitro and in vivo perspective.","finding":"","journal":"Immunopharmacology and immunotoxicology","studyType":"Clinical Study"},{"pmid":"40817571","year":"2025","title":"Ratiomeric Luminescent Monitoring of Cardiovascular Agents Exploiting Phosphorus and Nitrogen Co-Doped Carbon Quantum Dots as Nano-Sensors: Bioavailability Study in Rabbit Males.","finding":"","journal":"Luminescence : the journal of biological and chemical luminescence","studyType":"Clinical Study"},{"pmid":"39778696","year":"2025","title":"Identification of therapeutic target genes for age-related hearing loss through systematic genome-wide mendelian randomization of druggable genes.","finding":"","journal":"Experimental gerontology","studyType":"Clinical Study"},{"pmid":"38898746","year":"2024","title":"Protective efficacy of nafronyl in diabetic retinopathy through targeted inhibition of key enzymes.","finding":"","journal":"Biotechnology and applied biochemistry","studyType":"Clinical Study"},{"pmid":"37555794","year":"2023","title":"Validated spectrofluorimetric and resonance Rayleigh scattering methods for determining naftidrofuryl in varied pharmaceutical samples based on its interaction with erythrosin B.","finding":"","journal":"Luminescence : the journal of biological and chemical luminescence","studyType":"Clinical Study"}],"tags":[{"label":"naftidrofuryl","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"5-hydroxytryptamine receptor 2A","category":"target"},{"label":"HTR2A","category":"gene"},{"label":"C04AX21","category":"atc"},{"label":"Active","category":"status"},{"label":"Cerebrovascular disease","category":"indication"},{"label":"Chronic Occlusive Peripheral Arterial Disease","category":"indication"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Serotonin Agents","category":"pharmacology"},{"label":"Serotonin Antagonists","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"unknown","safety":{"safetySignals":[{"llr":101.993,"date":"","count":66,"signal":"Acute kidney injury","source":"DrugCentral FAERS","actionTaken":"Reported 66 times (LLR=102)"},{"llr":67.28,"date":"","count":30,"signal":"Hyperkalaemia","source":"DrugCentral FAERS","actionTaken":"Reported 30 times (LLR=67)"},{"llr":60.418,"date":"","count":24,"signal":"Lactic acidosis","source":"DrugCentral FAERS","actionTaken":"Reported 24 times (LLR=60)"}],"commonSideEffects":[{"effect":"Acute kidney injury","drugRate":"LLR 102","severity":"common"},{"effect":"Hyperkalaemia","drugRate":"LLR 67","severity":"common"},{"effect":"Lactic acidosis","drugRate":"LLR 60","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"nafronyl","offLabel":[],"synonyms":["naftidrofurile","nafronyl oxalate","nafronyl","naftidrofuryl","naphtidrofuryl","naftidrofuryl oxalate","naftidrofuryl hydrogen oxalate"],"timeline":[],"approvals":[],"brandName":"Nafronyl","ecosystem":[{"indication":"Cerebrovascular disease","otherDrugs":[{"name":"isoxsuprine","slug":"isoxsuprine","company":""},{"name":"tolazoline","slug":"tolazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Chronic Occlusive Peripheral Arterial Disease","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"5-hydroxytryptamine receptor 2A","targets":[{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"}],"modality":"Small Molecule","drugClass":"naftidrofuryl","explanation":"Imagine your blood vessels are like roads in your body. Nafronyl helps to widen these roads, making it easier for blood to flow and reach the areas that need it. This can help to reduce the risk of stroke and improve symptoms of peripheral artery disease.","oneSentence":"Nafronyl works by interacting with the 5-hydroxytryptamine receptor 2A to improve blood flow and reduce vascular resistance.","technicalDetail":"Nafronyl acts as a 5-HT2A receptor antagonist, which leads to vasodilation and improved blood flow through the reduction of vascular resistance."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1870","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=naftidrofuryl","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:53:06.593941","biosimilars":[],"competitors":[{"drugName":"phenoxybenzamine","drugSlug":"phenoxybenzamine","fdaApproval":"1953-01-26","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"naftidrofuryl","indications":{"approved":[{"name":"Cerebrovascular disease","source":"DrugCentral","snomedId":62914000,"regulator":"FDA"},{"name":"Chronic Occlusive Peripheral Arterial Disease","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"phenoxybenzamine","brandName":"phenoxybenzamine","genericName":"phenoxybenzamine","approvalYear":"1953","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"003746","UNII":"42H8PQ0NMJ","CHEBI":"CHEBI:91817","INN_ID":"2177","RXNORM":"7236","UMLSCUI":"C0027329","ChEMBL_ID":"CHEMBL1439099","KEGG_DRUG":"D05107","DRUGBANK_ID":"DB13588","PUBCHEM_CID":"4417","SNOMEDCT_US":"350627007","SECONDARY_CAS_RN":"3200-06-4","MESH_DESCRIPTOR_UI":"D009257"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.35 hours","clearance":"10.8 mL/min/kg","fractionUnbound":"0.2%","volumeOfDistribution":"0.98 L/kg"},"publicationCount":420,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C04AX21","allCodes":["C04AX21"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Dec","pmid":"41224747","title":"Naftidrofuryl mitigates LPS-induced pulmonary injury through macrophage polarization and NLRP3/TLR4 regulation, an in vitro and in vivo perspective.","journal":"Immunopharmacology and immunotoxicology"},{"date":"2025 Aug","pmid":"40817571","title":"Ratiomeric Luminescent Monitoring of Cardiovascular Agents Exploiting Phosphorus and Nitrogen Co-Doped Carbon Quantum Dots as Nano-Sensors: Bioavailability Study in Rabbit Males.","journal":"Luminescence : the journal of biological and chemical luminescence"},{"date":"2025 Feb","pmid":"39778696","title":"Identification of therapeutic target genes for age-related hearing loss through systematic genome-wide mendelian randomization of druggable genes.","journal":"Experimental gerontology"},{"date":"2024 Dec","pmid":"38898746","title":"Protective efficacy of nafronyl in diabetic retinopathy through targeted inhibition of key enzymes.","journal":"Biotechnology and applied biochemistry"},{"date":"2023 Oct","pmid":"37555794","title":"Validated spectrofluorimetric and resonance Rayleigh scattering methods for determining naftidrofuryl in varied pharmaceutical samples based on its interaction with erythrosin B.","journal":"Luminescence : the journal of biological and chemical luminescence"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Nafronyl (naftidrofuryl) is a small molecule drug that targets the 5-hydroxytryptamine receptor 2A. It is used to treat cerebrovascular disease and chronic occlusive peripheral arterial disease. The commercial status of nafronyl is unclear, but it is not FDA-approved. Key safety considerations include its short half-life of 1.35 hours. Nafronyl is a member of the naftidrofuryl drug class.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}